- Late Pelvic Toxicity After Bladder-Sparing Therapy in Patients With Invasive Bladder Cancer: RTOG 89-03, 95-06, 97-06, 99-06
[作者:Efstathiou, JA; Bae, K; Shipley, WU; Kaufman, DS; Hagan, MP; Heney, NM; Sandler, HM,期刊:Journal of clinical oncology, 页码:4055-4061 , 文章类型: Article,,卷期:2009年27-25]
- Purpose In selected patients with muscle-invasive bladder cancer, combined-modality therapy (transurethral resection bladder tumor [TURBT], radiation therapy, chemotherapy) with salvage cystectomy, if necessary, can achi...
- Final Results of Sequential Doxorubicin Plus Gemcitabine and Ifosfamide, Paclitaxel, and Cisplatin Chemotherapy in Patients With Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium
[作者:Milowsky, MI; Nanus, DM; Maluf, FC; Mironov, S; Shi, WJ; Iasonos, A; Riches, J; Regazzi, A; Bajorin, DF,期刊:Journal of clinical oncology, 页码:4062-4067 , 文章类型: Article,,卷期:2009年27-25]
- Purpose Sequential chemotherapy with doxorubicin and gemcitabine (AG) followed by ifosfamide, paclitaxel, and cisplatin (ITP) was previously demonstrated to be well tolerated in patients with advanced transitional cell c...
- Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
[作者:Escudier, B; Roigas, J; Gillessen, S; Harmenberg, U; Srinivas, S; Mulder, SF; Fountzilas, G; Peschel, C; Flodgren, P; Maneval, EC; Chen, I; Vogelzang, NJ,期刊:Journal of clinical oncology, 页码:4068-4075 , 文章类型: Proceedings Paper,,卷期:2009年27-25]
- Purpose Sunitinib has demonstrated antitumor activity in metastatic renal cell carcinoma (mRCC) when given at 50 mg/d on a 4-weeks-on 2-weeks-off regimen. Herein, we report results of an open-label, multicenter phase II ...
- Phase II Presurgical Feasibility Study of Bevacizumab in Untreated Patients With Metastatic Renal Cell Carcinoma
[作者:Jonasch, E; Wood, CG; Matin, SF; Tu, SM; Pagliaro, LC; Corn, PG; Aparicio, A; Tamboli, P; Millikan, RE; Wang, XM; Araujo, JC; Arap, W; Tannir, N,期刊:Journal of clinical oncology, 页码:4076-4081 , 文章类型: Article,,卷期:2009年27-25]
- Purpose To assess safety and efficacy of presurgical bevacizumab in patients with metastatic renal cell carcinoma (mRCC), and to explore the hypothesis that pretreatment of patients with antiangiogenic therapy will selec...
- Trends in Mastectomy Rates at the Mayo Clinic Rochester: Effect of Surgical Year and Preoperative Magnetic Resonance Imaging
[作者:Katipamula, R; Degnim, AC; Hoskin, T; Boughey, JC; Loprinzi, C; Grant, CS; Brandt, KR; Pruthi, S; Chute, CG; Olson, JE; Couch, FJ; Ingle, JN; Goetz, MP,期刊:Journal of clinical oncology, 页码:4082-4088 , 文章类型: Proceedings Paper,,卷期:2009年27-25]
- Purpose Recent changes have occurred in the presurgical planning for breast cancer, including the introduction of preoperative breast magnetic resonance imaging (MRI). We sought to analyze the trends in mastectomy rates ...
- Treatment of Fluorouracil-Refractory Patients With Liver Metastases From Colorectal Cancer by Using Yttrium-90 Resin Microspheres Plus Concomitant Systemic Irinotecan Chemotherapy
[作者:van Hazel, GA; Pavlakis, N; Goldstein, D; Olver, IN; Tapner, MJ; Price, D; Bower, GD; Briggs, GM; Rossleigh, MA; Taylor, DJ; George, J,期刊:Journal of clinical oncology, 页码:4089-4095 , 文章类型: Proceedings Paper,,卷期:2009年27-25]
- Purpose Liver metastases are the principal cause of death in patients with advanced colorectal cancer (CRC). Irinotecan is a chemotherapeutic agent used in the treatment of CRC and has demonstrated synergistic potential ...
- Phase II Study of Bevacizumab With Concurrent Capecitabine and Radiation Followed by Maintenance Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer: Radiation Therapy Oncology Group RTOG 0411
[作者:Crane, CH; Winter, K; Regine, WF; Safran, H; Rich, TA; Curran, W; Wolff, RA; Willett, CG,期刊:Journal of clinical oncology, 页码:4096-4102 , 文章类型: Proceedings Paper,,卷期:2009年27-25]
- Purpose The primary objective of this study was to assess the 1-year survival of patients with locally advanced, unresectable pancreatic cancer treated with the combination of bevacizumab, capecitabine, and radiation. Se...
- Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor Dynamics
[作者:Claret, L; Girard, P; Hoff, PM; Van Cutsem, E; Zuideveld, KP; Jorga, K; Fagerberg, J; Bruno, R,期刊:Journal of clinical oncology, 页码:4103-4108 , 文章类型: Proceedings Paper,,卷期:2009年27-25]
- Purpose We developed a drug-disease simulation model to predict antitumor response and overall survival in phase III studies from longitudinal tumor size data in phase II trials. Methods We developed a longitudinal expos...
- Racial Differences in Advanced Colorectal Cancer Outcomes and Pharmacogenetics: A Subgroup Analysis of a Large Randomized Clinical Trial
[作者:Sanoff, HK; Sargent, DJ; Green, EM; McLeod, HL; Goldberg, RM,期刊:Journal of clinical oncology, 页码:4109-4115 , 文章类型: Proceedings Paper,,卷期:2009年27-25]
- Purpose Racial disparities in colorectal cancer (CRC) survival are documented, but there are few data on comparative response to chemotherapy. A subgroup analysis of a multisite National Cancer Institute-sponsored trial ...
- Phase I Dose Escalation, Pharmacokinetic and Pharmacodynamic Study of Naptumomab Estafenatox Alone in Patients With Advanced Cancer and With Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer
[作者:Borghaei, H; Alpaugh, K; Hedlund, G; Forsberg, G; Langer, C; Rogatko, A; Hawkins, R; Dueland, S; Lassen, U; Cohen, RB,期刊:Journal of clinical oncology, 页码:4116-4123 , 文章类型: Proceedings Paper,,卷期:2009年27-25]
- Purpose Two phase I studies were conducted of ABR-217620 alone or in combination with docetaxel. This is a recombinant fusion protein consisting of a mutated variant of the superantigen staphylococcal enterotoxin E (SEA/...
- D-Dimer and Prothrombin Fragment 1+2 Predict Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis Study
[作者:Ay, C; Vormittag, R; Dunkler, D; Simanek, R; Chiriac, AL; Drach, J; Quehenberger, P; Wagner, O; Zielinski, C; Pabinger, I,期刊:Journal of clinical oncology, 页码:4124-4129 , 文章类型: Article,,卷期:2009年27-25]
- Purpose Venous thromboembolism (VTE) is a well-recognized complication of cancer. Laboratory parameters might be useful to assess the VTE risk in patients with cancer. The aim of this study was to investigate D-dimer and...
- Chronic Physical Effects and Health Care Utilization in Long-Term Ovarian Germ Cell Tumor Survivors: A Gynecologic Oncology Group Study
[作者:Matei, D; Miller, AM; Monahan, P; Gershenson, D; Zhao, QQ; Cella, D; Champion, VL; Williams, SD,期刊:Journal of clinical oncology, 页码:4142-4149 , 文章类型: Article,,卷期:2009年27-25]
- Purpose This study compares late effects of treatment on physical well-being and utilization of health care resources between ovarian germ cell tumor (OGCT) survivors and age/race/education-matched controls. Patients and...
- Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas
[作者:Sanson, M; Marie, Y; Paris, S; Idbaih, A; Laffaire, J; Ducray, F; El Hallani, S; Boisselier, B; Mokhtari, K; Hoang-Xuan, K; Delattre, JY,期刊:Journal of clinical oncology, 页码:4150-4154 , 文章类型: Article,,卷期:2009年27-25]
- Purpose Unexpected mutations affecting the isocitrate dehydrogenase (IDH1) gene at codon 132 have been found in 12% of glioblastomas. Patients and Methods IDH1 codon 132 sequencing was performed in a series of 404 patien...
- Talampanel With Standard Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma: A Multicenter Phase II Trial
[作者:Grossman, SA; Ye, XB; Chamberlain, M; Mikkelsen, T; Batchelor, T; Desideri, S; Piantadosi, S; Fisher, J; Fine, HA,期刊:Journal of clinical oncology, 页码:4155-4161 , 文章类型: Article,,卷期:2009年27-25]
- Purpose Recent data suggest that the glutamatergic system is important in the proliferation and migration of glioblastoma. Talampanel is a well-tolerated, oral alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AM...
|